Resultats de la cerca - Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward per Vivek Subbiah

Obtenir text complet

Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis per Kalevi Kairemo, Homer A. Macapinlac, Mohammed Gouda, Vivek Subbiah

Obtenir text complet

For what it’s worth: the complex area of medicine value assessment per Sreeram V Ramagopalan, Catrin Treharne, Jonathan Pearson-Stuttard, Vivek Subbiah

Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer per Edwin Lin, Ying-Chun Lo, Vivek Subbiah, Rajat Thawani, Aakash Desai

Obtenir text complet

Development of anti-cancer medicines in the current era per Bradley J. Monk, Manish R. Patel, Sarper Toker, Vivek Subbiah, Lucio N. Gordan

Obtenir text complet

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib per Tao Shen, Xueqing Hu, Xuan Liu, Vivek Subbiah, Blaine H. M. Mooers, Jie Wu

Obtenir text complet

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers per Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram Ramagopalan, Alind Gupta, Grace Hsu, Paul Arora, Vivek Subbiah

Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (¹⁸F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study per Kalevi Kairemo, Elmer B. Santos, Homer A. Macapinlac, Shreyaskumar Patel, Anthony P. Conley, David S. Hong, Vivek Subbiah

Obtenir text complet

Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial per Mirella Nardo, Camila Braganca Xavier, Bettzy Stephen, Jeffrey A. How, Justin Moyers, Vivek Subbiah, David S. Hong, Aung Naing

Obtenir text complet

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma per Blessie Elizabeth Nelson, Neha K. Reddy, Jason T. Huse, Behrang Amini, Mirella Nardo, Mohamed Gouda, Shiao-Pei Weathers, Vivek Subbiah

Obtenir text complet

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer per Sanjay Popat, Stephen V. Liu, Nicolas Scheuer, Grace G. Hsu, Alexandre Lockhart, Sreeram V. Ramagopalan, Frank Griesinger, Vivek Subbiah

Obtenir text complet

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy per Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R. Wilson, Sagar A. Naik, Vivek Subbiah, Matthew T. Campbell, Pavlos Msaouel, Parminder Singh, Omar Alhalabi

Obtenir text complet

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition per Niamh Coleman, Vivek Subbiah, Shubham Pant, Keyur Patel, Sinchita Roy-Chowdhuri, Sireesha Yedururi, Amber Johnson, Timothy A. Yap, Jordi Rodon, Kenna Shaw, Funda Meric-Bernstam

Obtenir text complet

732 Immune activation with plinabulin enhances anti-tumor response combining radiation with immune checkpoint blockade per Vivek Subbiah, Huiying Sun, Siqing Fu, Lan Huang, Hui Gao, Steven H Lin, Ziyi Li, Evan Cohen, James Reuben, June Lu, Ken Lloyd, James Tonra

A unified framework for pre-screening and screening tools in oncology clinical trials per Denis Horgan, Joseph N. Paulson, Arturo Loaiza-Bonilla, Christer Svedman, Umberto Malapelle, Frédérique Penault-Llorca, Hadi Mohamad Abu Rahsheed, Paul Hofman, Stan Kachnowski, Daniel Schneider, Vivek Subbiah

Obtenir text complet

Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development per Denis Horgan, Zorana Maravic, Ken Mastris, Hadi Mohamad Abu Rasheed, Carolina Reduzzi, Adda Bounedjar, Hesham Elghazaly, Alejandro Mohar, Roberto Pestana, Jonathan A. Lal, Umberto Malapelle, Ramin Asgary, Vivek Subbiah

Obtenir text complet

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer per Vivek Subbiah, Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria Cabanillas, Mimi Hu, Luz E. Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu

Obtenir text complet

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors per Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A. Piha‐Paul, John Wright, Senait N. Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric‐Bernstam, Aung Naing

Obtenir text complet

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. per Denis L Jardim, Jennifer J Wheler, Kenneth Hess, Apostolia M Tsimberidou, Ralph Zinner, Filip Janku, Vivek Subbiah, Aung Naing, Sarina A Piha-Paul, Shannon N Westin, Sinchita Roy-Chowdhuri, Funda Meric-Bernstam, David S Hong

Obtenir text complet

Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy per Milan Radovich, James Wacker, Jeffrey Solzak, Hongseok Tae, Jennifer R. Ribeiro, Todd Maney, Bradley Hancock, James Hamrick, George W. Sledge, Manmeet S. Ahluwalia, Stephen V. Liu, Emil Lou, Vivek Subbiah, Balazs Halmos, Daniel Magee, David B. Spetzler

Obtenir text complet